Referenser

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–916

2. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;473–488

3. T-cell mediated immunity. In: Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health & Disease. 6th ed. New York, NY: Garland Science Publishing; 2005;8:319–365

4. Emery P, Westhovens R, Leon G, et al. Beneficial effects of the selective co-stimulation modulator abatacept on biomarkers of rheumatoid arthritis immunopathology in patients with an inadequate response to methotrexate or TNF-inhibitor treatment. Poster # Sat 0074, EULAR 2005.

5. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition; N Engl J Med. 2005;353:1114–1123

6. Kremer JM, Genant HK, Moreland LW, et al. Effect of abatacept in patients with methotrexate resistant active rheumatoid arthritis; randomised trial. Ann Int Med. 2006;144:865–876

7. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis. 2007 Dec 17; [Epub ahead of print].

8. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Eng J Med 2003; 349:1907–1915

9. Dougados M, Keiserman M, Codding M. Efficacy of abatacept or infliximab treatment in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a 1-year double-blind, randomized, placebo-controlled trial. Rheumatology 2007;46(Suppl 1)

10. Dougados M, Schiff M, Luggen M, et al. Sustained efficacy along with improvements in disease activity score (DAS28) and patient (pt)-reported outcomes (PROs) with abatacept in rheumatoid arthritis (RA) patients with an inadequate response to anti-tumor necrosis factor (TNF) therapy: the long-term extension (LTE) of the ATTAIN trial. Rheumatology 2007;46(Suppl 1):i99

11. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy. Ann Rheum Dis. 2007 Oct 18 [Epub ahead of print].

12. Kremer J, Westhovens R, Luggen M, et al. Long-term Efficacy and Safety of Abatacept Through 3 Years of Treatment In Rheumatoid Arthritis Patients in the AIM and ATTAIN Trials. Arthritis Rheum 2007; 56 (9S): S300.

13. Westhovens R, Kremer J, Moreland L, et al. Maintained efficacy and safety of abatacept in rheumatoid arthritis patients receiving background methotrexate through 5 years of treatment. American College of Rheumatology and the Association of Rheumatology Health Professionals (acr/arhp) Annual Scientific Meeting 2007 Boston, Massachusetts. November 6–11. Abstract 950

14. Schiff M, Pritchard C, Zhou X, et al. The efficacy of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: The ARRIVE trial. American College of Rheumatology and the Association of Rheumatology Health Professionals (acr/arhp) Annual Scientific Meeting 2007 Boston, Massachusetts. November 6–11. Abstract 942

15. Kremer JM, Genant HK, Moreland LW, et al. Two-year follow-up of patients with rheumatoid arthritis receiving a combination of abatacept and methotrexate. Arthritis Rheum, in press.

16. Genant HK, et al. Non-progression of structural damage over 2 years with abatacept in rheumatoid arthritis patients with an inadequate response to methotrexate in the AIM trial. Arth Rheum 2006;54(Suppl 9):S408

17. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2007 Nov 29; [Epub ahead of print].

18. Simon TA, et al. Descriptive trend analysis of infections and malignancies in the abatacept clinical development program. American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting 2007 Boston, Massachusetts. November 6–11. Abstract 1039.